Wall Street analysts forecast that TESARO Inc (NASDAQ:TSRO) will report $51.78 million in sales for the current fiscal quarter, Zacks reports. Nine analysts have issued estimates for TESARO’s earnings, with the highest sales estimate coming in at $59.17 million and the lowest estimate coming in at $46.07 million. TESARO reported sales of $4.23 million in the same quarter last year, which indicates a positive year-over-year growth rate of 1,124.1%. The business is expected to issue its next quarterly earnings results after the market closes on Tuesday, February 27th.

On average, analysts expect that TESARO will report full year sales of $51.78 million for the current fiscal year, with estimates ranging from $221.37 million to $299.10 million. For the next year, analysts forecast that the business will post sales of $388.01 million per share, with estimates ranging from $274.00 million to $529.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that cover TESARO.

Several equities analysts have commented on the company. Zacks Investment Research downgraded TESARO from a “hold” rating to a “sell” rating in a report on Tuesday, October 17th. HC Wainwright assumed coverage on TESARO in a report on Thursday, October 12th. They set a “buy” rating and a $158.00 price target on the stock. Piper Jaffray Companies reiterated a “neutral” rating and set a $117.00 price target on shares of TESARO in a report on Monday, October 23rd. Barclays assumed coverage on TESARO in a report on Monday, October 23rd. They set an “equal weight” rating and a $135.00 price target on the stock. Finally, Cann reiterated a “buy” rating and set a $199.00 price target on shares of TESARO in a report on Tuesday, November 7th. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $149.97.

Shares of TESARO (NASDAQ TSRO) traded up $2.88 during mid-day trading on Tuesday, reaching $58.89. The company’s stock had a trading volume of 974,449 shares, compared to its average volume of 1,299,344. TESARO has a one year low of $55.02 and a one year high of $192.94. The company has a debt-to-equity ratio of 0.34, a quick ratio of 4.35 and a current ratio of 4.73. The firm has a market capitalization of $3,050.00, a P/E ratio of -6.99 and a beta of 1.25.

In other news, SVP Martin H. Jr. Huber sold 829 shares of the firm’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $85.24, for a total value of $70,663.96. Following the sale, the senior vice president now owns 8,101 shares in the company, valued at $690,529.24. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 40.50% of the company’s stock.

Several institutional investors have recently made changes to their positions in TSRO. Janus Henderson Group PLC acquired a new stake in shares of TESARO in the second quarter worth $100,301,000. TimesSquare Capital Management LLC acquired a new stake in shares of TESARO in the third quarter worth $33,911,000. Pictet Asset Management Ltd. grew its stake in shares of TESARO by 58.1% in the third quarter. Pictet Asset Management Ltd. now owns 630,904 shares of the biopharmaceutical company’s stock worth $81,450,000 after acquiring an additional 231,799 shares during the last quarter. BlackRock Inc. lifted its position in TESARO by 5.6% in the fourth quarter. BlackRock Inc. now owns 4,067,066 shares of the biopharmaceutical company’s stock worth $337,039,000 after purchasing an additional 213,920 shares during the period. Finally, State Street Corp lifted its position in TESARO by 17.9% in the second quarter. State Street Corp now owns 1,168,913 shares of the biopharmaceutical company’s stock worth $163,496,000 after purchasing an additional 177,057 shares during the period.

COPYRIGHT VIOLATION WARNING: This story was first posted by Watch List News and is the property of of Watch List News. If you are reading this story on another site, it was illegally copied and reposted in violation of United States and international trademark & copyright legislation. The original version of this story can be accessed at https://www.watchlistnews.com/zacks-analysts-anticipate-tesaro-inc-tsro-will-announce-quarterly-sales-of-51-78-million/1855894.html.

TESARO Company Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Get a free copy of the Zacks research report on TESARO (TSRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.